Abatacept for the treatment of juvenile idiopathic arthritis
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- Referral date:
- 01 June 2008
- Topic area
- Musculoskeletal
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Project Team
- Communications manager:
- TBC
- Executive Lead:
- TBC
- Project manager:
- TBC
- Technical Lead:
- TBC
Stakeholders
- Manufacturers/sponsors
- Bristol Myers Squibb Pharmaceuticals (abatacept)
- Others
- Cardiff LHB
- Department of Health
- Doncaster PCT
- Welsh Assembly Government
- Patient/carer groups
- Action for Children
- Action for Sick Children
- Action on Pain
- Afiya Trust
- Arthritic Association
- Arthritis and Musculoskeletal Alliance (ARMA)
- Arthritis Care
- BackCare
- Black Health Agency
- British Ethnic Health Awareness Foundation (BEHAF)
- Children’s Society
- Children’s Chronic Arthritis Association
- Chinese National Healthy Living Centre
- Confederation of Indian Organisations
- Equalities National Council
- Leonard Cheshire Disability
- Muslim Council of Great Britain
- Muslim Health Network
- National Children’s Bureau
- National Parent and Carer Council
- National Parent Partnership Network
- National Rheumatoid Arthritis Society
- Pain Concern
- Pain Relief Foundation
- RADAR - Royal Association for Disability and Rehabilitation
- Skill: National Bureau for Students with Disabilities
- South Asian Health Foundation
- Specialised Healthcare Alliance
- WellChild
- Professional groups
- British Health Professionals in Rheumatology
- British Institute of Musculoskeletal Medicine
- British Orthopaedic Association
- British Pain Society
- British Society for Paediatric and Adolescent Rheumatology
- British Society for Rheumatology
- British Society of Rehabilitation Medicine
- College of Occupational Therapists
- Physiotherapy Pain Association
- Primary Care Rheumatology Society
- Rheumatoid Arthritis Surgical Society
- Royal Society of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Paediatrics & Child Health
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine – Intellectual Disabilities Forum
- United Kingdom Clinical Pharmacy Association
- Associated Guideline Groups
- National Clinical Guidelines Centre for Acute and Chronic Conditions
- Associated Public Health Groups
- None
- Comparator manufacturer(s)
- Abbott Pharmaceuticals (adalimumab)
- Generics (UK) (sulfasalazine)
- IVAX Pharmaceuticals (sulfasalazine)
- Mayne Pharma (methotrexate)
- Medac UK (methotrexate)
- Novartis Pharmaceuticals (ciclosporin)
- Pfizer (sulfasalazine, methotrexate)
- Sanofi Aventis (hydroxychloroquine, leflunomide)
- Schering-Plough (infliximab)
- Teva UK (sulfasalazine)
- Wockhardt UK (methotrexate)
- Wyeth Laboratories (etanercept)
- Evidence Review Group
- NHS Centre for Reviews & Dissemination and Centre for Health Economics –York
- National Institute for Health Research Health Technology Assessment Programme
- General
- Board of Community Health Councils in Wales
- British National Formulary
- Department of Health,Social Services and Public Safety for Northern Ireland
- Medicines and Healthcare products Regulatory Agency (MHRA)
- National Association of Primary Care
- National Public Health Service for Wales
- NHS Alliance
- NHS Confederation
- NHS Purchasing and Supply Agency
- NHS Quality Improvement Scotland
- Scottish Medicines Consortium
- Relevant research groups
- Arthritis Research Campaign
- Bone Research Society
- MRC Clinical Trials Unit
- National Institute of Health Research
- United Kingdom Clinical Research Network
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 7 August 2009 | The above topic was referred to NICE as part of the 17th wave referrals. The manufacturer of abatacept has informed us that they are not in a position to submit evidence in line with the current schedule for this STA because of a delay in the regulatory process. This STA is therefore suspended. |
| 7 July 2010 | The marketing authorisation for abatacept in this therapeutic area suggests limited use of this drug for a small population of those with juvenile idiopathic arthritis. Following discussions with the Department of Health, we have therefore concluded that this topic should be removed from the work programme. |
For further information on our processes and methods, please see our CHTE processes and methods manual